Poor
Needs Revision
Patient Risk:
Moderate
Summary
Only the first medical claim is partially alignable with the label excerpt (DMD use exists, but the label requires a confirmed exon 53-amenable DMD mutation). The remaining claims concern financial assistance and are not addressed in the provided prescribing-information excerpts.
Category Scores
Accurate Statements
Vyondys 53 (golodirsen) is a prescription drug used for Duchenne muscular dystrophy (DMD).
Indications and Usage: VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed DMD gene mutation amenable to exon 53 skipping. (Section 1)
Unsupported Statements
Financial assistance for Vyondys is typically delivered through manufacturer support programs.
No information about financial assistance, reimbursement, or manufacturer support programs appears in the provided prescribing information excerpts.
Manufacturer support programs for Vyondys can help eligible patients with out-of-pocket costs.
No information about out-of-pocket costs or eligibility criteria for financial assistance appears in the provided prescribing information excerpts.
In some cases, manufacturer support programs for Vyondys can provide pathways for patients who are uninsured or underinsured.
No information about uninsured/underinsured pathways appears in the provided prescribing information excerpts.
Contradictions
Important Omissions
The indication as stated in the label requires: (1) confirmed mutation of the DMD gene that is amenable to exon 53 skipping (and the accelerated-approval context). The claim omits these qualifying conditions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The medication use claim omits the label’s required genetic mutation criterion, which could lead to misinterpretation of who the drug is indicated for. The financial-assistance claims are not label-supported but are less directly safety-relevant based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Non-label financial-assistance claims are made without support in the provided prescribing information; the medical indication claim omits the label’s required mutation-amenable-to-exon-53-skipping condition.
Suggested Improvement
Limit the medical indication statement to the label’s full qualifying language (confirmed DMD gene mutation amenable to exon 53 skipping). Remove or re-verify any financial-assistance/manufacturer-program statements, as they are not contained in the provided FDA-approved prescribing information excerpts.